Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Link Pharma Chem Ltd has filed copies of newspaper advertisements (published on 27 May 2025 in Business Standard and Loksatta) for its audited financial results for the quarter and full year ended 31 March 2025, as required under SEBI Listing Regulations. For FY25, total income from operations fell to Rs. 2,543.34 lakhs from Rs. 2,989.77 lakhs in FY24. The company reported a net loss of Rs. 102.73 lakhs after tax for FY25, an improvement from the Rs. 136.29 lakhs loss in FY24, with EPS improving from Rs. -3.07 to Rs. -2.31. For Q4 FY25 alone, revenue was Rs. 644.66 lakhs and the company slipped back into a loss of Rs. 35.02 lakhs after tax, compared to a profit of Rs. 26.00 lakhs in the preceding Q3 FY25.
This is a routine regulatory filing with no new business action — it merely publishes already-audited results in newspapers. For shareholders, the takeaway is mixed: full-year losses narrowed but revenue shrank, and Q4 swung back to a loss after a profitable Q3, which may weigh negatively on sentiment.